| Company Name: | Labopharm, Incorporated | | Ticker Symbol: | DDSS | | | WWW Address: | www.labopharm.com | | CEO: | James R. Howard-Tripp | | No. of Employees: | 168 | | Common Issue Type: | CS | | Business Description: | A specialty pharmaceutical company, which develops drugs by incorporating its proprietary controlled-release technologies.
|
| | | Industry Information: | DRUGS - Drug Related Products & Accessories [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.41 |  0.0 | 1.25 | 1.47 | 1.41 | 1.46 | 1.40 | 127263 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 81.0 | 57.4 | 1.91 | -0.58 | 0.00 | 0.0 | 0.0 | 2.95 - 0.32 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.41 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 81.0 | mil |
| Latest Shares Outstanding | 57.4 | mil |
| Earnings pS (EPS) | -0.58 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 107,923 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 15 | mil |
| Domestic Sales | 3 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 134.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 51.90 | % |
| Gross Profit Margin | 66.8 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -65.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -168.7 | % |
| Current Ratio | 1.4 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 144.0 | % |
| Working Capital pS | 0.17 | $ |
| Cash pS | 0.24 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.16 | $ |
| Cash Flow pS | -0.48 | $ |
| Free Cash Flow pS | -0.37 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -8.74 | |
| Price/Cash Flow | -3.0 | |
| Price/Free Cash Flow | -3.8 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 99 | 2,651 | 1,217 |
| 4 Weeks | 1.73 | 1.37 | 1.55 | -9.0 | 85 | 3,370 | 53,919 |
| 13 Weeks | 2.25 | 1.21 | 1.43 | -1.4 | 92 | 5,787 | 347,247 |
| 26 Weeks | 2.95 | 1.00 | 1.85 | -23.8 | 63 | 5,970 | 740,276 |
| 52 Weeks | 2.95 | 0.32 | 0.47 | 200.0 | 243 | 3,533 | 876,133 |
| YTD | 2.95 | 0.76 | - | -22.5 | 63 | 3,618 | 817,697 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.42 | 1.44 | 1.56 | 1.75 | 1.58 | 1.91 | 1.85 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 24.87 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 21.24 |
| R&D | 0.00 | NA | -6.66 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.7 | -30.4 | -5.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.10 | -0.01 | 0.06 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 44.05 |
| Current Ratio | 2.4 |
| Quick Ratio (Acid Test) | 2.3 |
| Liquidity Ratio (Cash) | 2.08 |
| Receivables Turnover | 4.8 |
| Average Collection Period | 75 |
| Working Capital/Equity | 226.3 |
| Working Capital pS | 0.45 |
| Cash-Flow pS | -0.56 |
| Free Cash-Flow pS | -0.52 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.70 |
| Financial Leverage Ratio (Assets/Equity) | 5.1 |
| Debt Ratio | 80.5 |
| Total Debt/Equity (Gearing Ratio) | 2.15 |
| LT Debt/Equity | 1.88 |
| LT Debt/Capital Invested | 88.5 |
| LT Debt/Total Liabilities | 45.5 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 6.49 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.24 |
| Tobin's Q Ratio | 1.41 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.26 |
| Enterprise Value (EV)/Free Cash Flow | -2.10 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -8.74 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -3.0 |
| Price/Free Cash Flow Ratio - LTM | -3.8 |
| Price/Sales Ratio | 4.22 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.37 |
| Current Liabilities pS | 0.31 |
| Tangible Book Value pS - LTM | -0.16 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.56 |
| Cash pS - LTM | 0.24 |
| Cash Flow pS - LTM | -0.48 |
| Free Cash Flow pS - LTM | -0.37 |
| Earnings pS (EPS) | -0.58 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -163.21 |
| Free Cash Flow Margin 5YEAR AVG | -372.10 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.62 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.56 |
| Return on Capital Invested (ROCI) | -103.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -65.7 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -58.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -40.8 |
| Gross Profit Margin | 66.8 |
| Gross Profit Margin - 5YEAR AVRG. | 70.3 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.1 |
| Effective Tax Rate - 5YEAR AVRG. | -4.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 245 |
| Revenue per Employee | 107,923 |
| Net Income per Employee | -198,679 |
| Average Collection Period | 82 |
| Receivables Turnover | 4.8 |
| Day's Inventory Turnover Ratio | 163 |
| Inventory Turnover | 2.2 |
| Inventory/Sales | 8.0 |
| Accounts Payble/Sales | 19.61 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.72 |
| Fixed Assets Turnover | 1.26 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 2.63 |
| Revenue per $ Plant | 2.16 |
| Revenue per $ Common Equity | 1.62 |
| Revenue per $ Capital Invested | 0.56 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 119.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 136.6 |
| Research & Devlopment (R&D) as % of Revenue | 106.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 106.5 |
|
|  
|
| |
 |  |